insights_auto
Miks on DRUG tõusnud? 4,87%?
Uurige põhjalikumaltchevron_right
DRUG:CNSX
Bright Minds Biosciences Inc
77,10 CA$
arrow_upward
+4,87%(+3,58) 1 p
9. okt, 16:00:00 GMT −4 · CAD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse DRUG põhistatistika genereerimine…
Ava
76,13 CA$
Kõrge
77,76 CA$
Madal
76,13 CA$
Turu kapit.
760,52 mln
Keskm. maht
865,00
Maht
400,00
52 näd kõrgeim
170,00 CA$
52 näd madalaim
68,02 CA$
Aktsiatulu
−2,90 CA$
Töötajate arv
26
Ava
76,13 CA$
Kõrge
77,76 CA$
Madal
76,13 CA$
Turu kapit.
760,52 mln
Keskm. maht
865,00
Maht
400,00
52 näd kõrgeim
170,00 CA$
52 näd madalaim
68,02 CA$
Aktsiatulu
−2,90 CA$
Töötajate arv
26
Uudised
Veebiallikatest ja uudistepartneritelt
CryptoRank
·
28 minuti eest
TruGolf completes Polymath acquisition, bringing tokenization infrastructure into Nasdaq-listed company
TradingView
·
51 minuti eest
Key facts: Goldman, Barclays Back NASDAQ:PLTR; CTO Defends Maven AI
Bloomberg.com
·
20 minuti eest
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profiil
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Teave üksuse Bright Minds Biosciences Inc kohta